CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in patients with stage I diffuse large-B-cell lymphoma
The role of rituximab in combination with CHOP-like chemotherapy regimens in patients with stage I diffuse large-B cell lymphoma remains to be defined.We aimed to compare CHOP-like chemotherapy and rituximab (R-CHOP) with CHOP-like chemotherapy alone in these patients.We retrospectively analyzed 140 untreated patients with stage I diffuse large-B-cell lymphoma (DLBCL).Seventy-eight patients were treated by R-CHOP regimen and 62 patients received CHOP-like chemotherapy alone.Ninety-one patients received additional radiotherapy at the end of chemotherapy.Median age at diagnosis was 52 years.Complete remission (CR) rate was 77% both in patients received R-CHOP chemotherapy and in patients with CHOP-like chemotherapy.After a median follow-up of 55 months,patients received R-CHOP chemotherapy had similar 5-year progression-free survival (PFS) (76% vs 85%; log-rank P=0.215) and 5-year overall survival (90% vs 96%; log-rank P=0.175) compared with those with CHOP-like chemotherapy alone.Patients with radiotherapy had significantly increased 5-year PFS compared with those who had chemotherapy alone (86% vs 71 %; log-rank P=0.005).These results suggest that CHOP- like chemotherapy alone could be as effective as R-CHOP chemotherapy and additional radiotherapy is necessary for stage I DLBCL patients.
diffuse large B-cell lymphoma limited stage RCHOP radiotherapy prognosis
B.Jia S.Yang S.Y.Zhou Y.Qin C.G.Zhang H.Lin S.S.Chen L.Gui S.X.Hu X.H.He Y.K.Shi S.Y.Kang M.Dong Y.X.Li W.H.Wang J.L.Yang L.Q.Zhou P.Liu
Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & P Department of Medical Record Library,Cancer Institute & Hospital,CAMS & PUMC ,Beijing,China Department of Radiotherapy, Cancer Institute & Hospital, CAMS & PUMC, Beijing, China
国内会议
中国老年学学会老年肿瘤专业委员会(CGOS)2014年年会暨第八届中国老年肿瘤学大会
北京
英文
2-18
2014-04-01（万方平台首次上网日期，不代表论文的发表时间）